Keramedics is new South Korean-based hair growth company and today they publish official press release for entering Phase I clinical trials for their Keratin based hair growth treatment with a name ’HK1’.
Their official press release:
-Keramedics announced on the 19th that it has applied for a phase 1 clinical trial plan (IND) for the innovative new drug candidate 'HK1', which is being developed as an injectable for hair loss treatment, to the Ministry of Food and Drug Safety. This clinical trial will be conducted at the Department of Dermatology at Chung-Ang University Hospital with the purpose of evaluating the safety and tolerability of HK1 on approximately 24 healthy Korean and Caucasian adults.
HK1, which Keramedics is developing as a new drug, is a substance using keratin, a component of human hair. This method induces hair growth and suppresses additional hair loss by injecting hair loss patients with keratin, which is produced by the cytokine 'TGF-BETA 2' during the resting phase when hair stops growing.
In a cell experiment, when cells were treated with HK1, a keratin component, aggregation of epidermal blast cells involved in hair growth and aggregation of dermal papilla cells occurred. This has been shown to promote hair growth factors and stem cell activating factors in hair roots.
In addition, in an animal experiment using rats, a higher hair growth effect was confirmed in the group injected with keratin when compared to mice that were injected once with keratin and mice that applied a conventional hair loss treatment (minoxidil) every day for 28 days. The research results were published in Nature Communication Biology (November 2022).
The company plans to successfully pursue this clinical trial and at the same time develop HK1 as a global innovative new drug through open innovation strategies, including technological partnerships.
CEO Han Song-wook of Keramedics said, "HK1 is an endogenous substance, so there is no need to worry about side effects, and it is composed of a polymer that promotes hair growth factors and stem cell activating factors, so it promotes a wide range of hair loss improvement effects." “We expect to be able to address unmet medical needs by selectively and effectively resolving hair loss-related diseases,” he said.
www.hankyung.com
Official Keramedics website:
http://www.keramedix.co.kr/board/board_view?code=gallery&no=2
Official link to the study:
https://www.nature.com/articles/s42003-022-04232-9#change-history
Great news from my perspective. What is your opinion about this company and perspective of HK1? Will it be game changer on long-term and give good amount of regrowth?
Their official press release:
-Keramedics announced on the 19th that it has applied for a phase 1 clinical trial plan (IND) for the innovative new drug candidate 'HK1', which is being developed as an injectable for hair loss treatment, to the Ministry of Food and Drug Safety. This clinical trial will be conducted at the Department of Dermatology at Chung-Ang University Hospital with the purpose of evaluating the safety and tolerability of HK1 on approximately 24 healthy Korean and Caucasian adults.
HK1, which Keramedics is developing as a new drug, is a substance using keratin, a component of human hair. This method induces hair growth and suppresses additional hair loss by injecting hair loss patients with keratin, which is produced by the cytokine 'TGF-BETA 2' during the resting phase when hair stops growing.
In a cell experiment, when cells were treated with HK1, a keratin component, aggregation of epidermal blast cells involved in hair growth and aggregation of dermal papilla cells occurred. This has been shown to promote hair growth factors and stem cell activating factors in hair roots.
In addition, in an animal experiment using rats, a higher hair growth effect was confirmed in the group injected with keratin when compared to mice that were injected once with keratin and mice that applied a conventional hair loss treatment (minoxidil) every day for 28 days. The research results were published in Nature Communication Biology (November 2022).
The company plans to successfully pursue this clinical trial and at the same time develop HK1 as a global innovative new drug through open innovation strategies, including technological partnerships.
CEO Han Song-wook of Keramedics said, "HK1 is an endogenous substance, so there is no need to worry about side effects, and it is composed of a polymer that promotes hair growth factors and stem cell activating factors, so it promotes a wide range of hair loss improvement effects." “We expect to be able to address unmet medical needs by selectively and effectively resolving hair loss-related diseases,” he said.
케라메딕스, 케라틴 성분 탈모치료 주사제 임상 1상 IND 신청
케라메딕스, 케라틴 성분 탈모치료 주사제 임상 1상 IND 신청 , 비임상에서 미녹시딜 대비 뛰어난 발모 효능 확인
Official Keramedics website:
http://www.keramedix.co.kr/board/board_view?code=gallery&no=2
Official link to the study:
https://www.nature.com/articles/s42003-022-04232-9#change-history
Great news from my perspective. What is your opinion about this company and perspective of HK1? Will it be game changer on long-term and give good amount of regrowth?